Astellas Pharma Gmbh

Koichiro Mukoyoshi

Hisashi Takasugi

Akira Tanaka

Yoshikazu Inoue

Shigeki Satoh

Fumiyuki Shirai

Yutaka Nakajima

Naoki Ishibashi

Yoshiteru Eikyu

Takayuki Inoue

Yasuharu Urano

Hiroshi Sasaki

Yuki Sawada

Kazunori Kamijo

Shohei Shirakami

Yasuyuki Higashi

Fumie Takahashi

Keiko Hatanaka

Takashi Kikuchi

Tsuyoshi Kitamura

Takeshi Kawakami

Hisao Hamaguchi

Masataka Morita

Takashi Tojo

Takeshi Hondo

Shigeki Kunikawa

Kazuo Nakai

Hitoshi Sawada

Katsuhiko Gato

Hironobu Yasuda

Akira Okimoto

[Problem] A salt or crystal of a compound which is highly stable in a solid state and useful as a bulk material for the preparation of a pharmaceutical product is provided. [Means for Solution] 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide succinate, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide, and 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrochloride and crystals thereof are useful as a bulk material for the preparation of a solid preparation, in particular, a solid dispersion preparation. Furthermore, the crystal of the hydrobromide has excellent stability in a solid state and is useful as a bulk material for the preparation of a pharmaceutical product.

Crystal of fused pyridine compound salt

The invention relates to compound of the formula (I) or its salt, wherein &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, -M-, &#x2014;X&#x2014; and &#x2014;Y&#x2550; are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases. 

Heterocyclic Janus Kinase 3 inhibitors

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia). 

Heterocyclic janus kinase 3 inhibitors

Compounds having the formula (I): wherein

HDAC inhibitor

A compound having the formula (I): wherein

Growing community of inventors

Tokyo, Japan

Koichiro Mukoyoshi